Genetic testing for embryo selection in women undergoing IVF
Official title: GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical Trial
Run by Genomic Prediction Inc. · NCT06141135 · Data updated 2026-11-12
This study is testing if using genetic testing to choose the best embryo for transfer can help women aged 35 to 40 have better pregnancy outcomes during IVF compared to standard methods.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 35 Years to 40 Years |
| Sex | Women only |
| Enrollment | 240 (estimated) |
| Sponsor | Genomic Prediction Inc. Industry-sponsored |
| Locations | 1 site (Waltham, Massachusetts) |
| Status | Recruiting |
| Started | November 15, 2023 |
| Main results expected | November 15, 2025 |
| Study ends | November 15, 2026 |
| Registry record updated | August 26, 2025 |
| Trial ID | NCT06141135 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women aged 35 to 40 who are undergoing IVF and have at least one evaluable blastocyst.
✕Probably not a fit
Patients who may not benefit include those using donor oocytes, gestational carriers, or those with a history of recurrent pregnancy loss or implantation failure.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The GETSET trial is a randomized clinical trial aimed at evaluating the outcomes of preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer among women aged 35 to 40. A total of 240 participants will be recruited and divided into two groups: one receiving standard embryo transfer and the other undergoing genetic testing to select the best quality euploid blastocyst for transfer. The trial will assess the effectiveness of this genetic testing approach in improving pregnancy outcomes compared to traditional methods.
Why it matters
Potential benefit: If successful, this study could enhance the chances of successful pregnancies for women undergoing IVF by ensuring the transfer of genetically healthy embryos.
How similar studies have gone: Other studies have shown promising results with preimplantation genetic testing approaches, indicating potential benefits in embryo selection.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women undergoing IVF of between 35 and 40 years of age at IVF cycle start * Utilization of Intracytoplasmic Sperm Injection ICSI (recommended) or ---Traditional IVF * Utilization of ejaculated or testicular sperm * Utilization of autologous or donor sperm * All Controlled Ovarian Hyperstimulation (COH) protocols Exclusion Criteria: * Utilization of donor oocytes * Utilization of gestational carrier * Recurrent Pregnancy Loss (RPL) defined as ≥ 3 consecutive miscarriages * Recurrent Implantation Failure (RIF) defined as ≥ 3 more failed embryo transfers * Preimplantation genetic testing for monogenic/single gene disorders (PGT-M) * Translocation carriers
Where it's running
-
Boston IVF
Waltham, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Nathan Treff, PhD — Genomic Prediction Clinical Labortory
- Study coordinator: Talia Metzgar
- Email: talia@genomicprediction.com
- Phone: (973) 529- 4223
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI into Ultrasound Diagnostics in Reproductive Medicine
Researchers are testing AI tools that analyze transvaginal ultrasound images to help detect endometriosis, adenomyosis, uterine masses, and pregnancy-related receptivity in women aged 18-45.
-
Tadalafil to increase uterine lining and improve frozen embryo transfer success
This test sees if adding daily tadalafil to standard estrogen helps women with unexplained infertility using good-quality day‑5 frozen embryos get a thicker uterine lining and better transfer outcomes.
-
FET-LET-2x2: Testing natural vs medicated natural cycles for frozen embryo transfer
This study tests four approaches to preparing the uterus for frozen embryo transfer to see which yields the best pregnancy rate in women undergoing IVF.
-
Integrative care guided by biological aging markers for unexplained female infertility
This trial tests whether measuring telomeres and other biological aging markers can guide a personalized integrative treatment to help women aged 25–42 with persistent unexplained infertility improve their chances of pregnancy.
-
How fitness, heart health, and mental well-being relate to assisted fertility treatments
This study tries to see if physical activity, cardiorespiratory fitness, cardiovascular health, sleep, and stress affect pregnancy chances for women undergoing assisted fertility treatments.
-
How attitudes toward artificial intelligence relate to anxiety and quality of life in women receiving infertility treatment
This study will test whether women's attitudes toward artificial intelligence are linked to their anxiety and quality of life while undergoing infertility treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.